Clinical Trials
199 trialsA Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
City of Hope Medical Center
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
City of Hope Medical Center
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
City of Hope Medical Center
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Ohio State University Comprehensive Cancer Center
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes
City of Hope Medical Center
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Roswell Park Cancer Institute
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
H. Lee Moffitt Cancer Center and Research Institute
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Roswell Park Cancer Institute
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Fred Hutchinson Cancer Center
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
Wake Forest University Health Sciences
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Roswell Park Cancer Institute
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Roswell Park Cancer Institute
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Texas Southwestern Medical Center
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Fred Hutchinson Cancer Center
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Wake Forest University Health Sciences
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins